Department of Urology, National Taiwan University Hospital, and National Taiwan University College of Medicine, Taipei, Taiwan.
Urolithiasis. 2013 Jun;41(3):247-52. doi: 10.1007/s00240-013-0554-y. Epub 2013 Mar 21.
The objective of this study is to evaluate the effects of solifenacin on double-J stent-related symptoms following uncomplicated ureterosocpic lithotripsy (URSL). A total of 70 patients who underwent double-J ureteral stent insertion following URSL were consecutively recruited and received solifenacin postoperatively. Another 70 age- and sex-matched subjects without solifenacin therapy were enrolled as a control group. The clinical data including stone and stent characteristics were collected. All subjects completed the brief-form Ureteral Symptom Score Questionnaire (Chinese-version) to assess the lower urinary tract symptoms, stent-related body pain and hematuria 2 weeks after operation. The severity of stent-related symptoms was compared between two groups. The mean age was 53.8 in solifenacin group and 53.4 years in the control group (p = 0.87). The stone characteristics, stent size, position and curl completeness were similar in both groups. Compared to the control group, solifenacin group had significantly lower total symptom score, urgency and urge incontinence scores. As for stent-related body pain, solifenacin group had significantly less flank, abdominal, urethral pain and hematuria scores (all p < 0.05). The solifenacin versus control group showed significant benefits in lower urinary tract symptoms, stent-related pain and hematuria in both genders (all p < 0.05). Four subjects encountered minor adverse events (5.7 %) and one had urinary retention (1.4 %) in solifenacin group. For patients undergoing URSL and double-J stent indwelling, postoperative solifenacin use was effective and well-tolerated for the treatment of lower urinary tract symptoms, stent-related body pain and hematuria irrespective of genders.
本研究旨在评估索利那新对单纯输尿管镜碎石术后双 J 支架相关症状的影响。连续招募了 70 例接受 URSL 后行双 J 输尿管支架置入术的患者，并在术后接受索利那新治疗。另招募 70 例年龄和性别匹配且未接受索利那新治疗的患者作为对照组。收集临床资料，包括结石和支架特征。所有患者均在术后 2 周完成简短版下尿路症状评分问卷（中文版）以评估下尿路症状、支架相关躯体疼痛和血尿。比较两组患者的支架相关症状严重程度。索利那新组的平均年龄为 53.8 岁，对照组为 53.4 岁（p=0.87）。两组的结石特征、支架大小、位置和卷曲完整性相似。与对照组相比，索利那新组的总症状评分、尿急和急迫性尿失禁评分明显较低。在支架相关躯体疼痛方面，索利那新组的腰部、腹部、尿道疼痛和血尿评分明显较低（均 p<0.05）。在男女患者中，索利那新组在改善下尿路症状、支架相关疼痛和血尿方面均优于对照组（均 p<0.05）。索利那新组有 4 例（5.7%）发生轻微不良事件，1 例（1.4%）发生尿潴留。对于接受 URSL 和双 J 支架留置的患者，术后使用索利那新治疗可有效缓解下尿路症状、支架相关躯体疼痛和血尿，且无论性别如何，患者均能耐受。
